{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:43:16Z","timestamp":1781944996766,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":650,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41379-020-00679-5","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T11:04:51Z","timestamp":1601291091000},"page":"823-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Camila C.","family":"Simoes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swan N.","family":"Thung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Fiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-00679-5_bib1","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1038\/s41379-020-00679-5_bib2","first-page":"524","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib3","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1038\/s41379-020-00679-5_bib4","doi-asserted-by":"crossref","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999\u20132016: observational study","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ"},{"key":"10.1038\/s41379-020-00679-5_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4254\/wjh.v7.i3.566","article-title":"Treatment of hepatocellular carcinoma: steps forward but still a long way to go","volume":"7","author":"Mlynarsky","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1038\/s41379-020-00679-5_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41379-020-00679-5_bib7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1038\/s41379-020-00679-5_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: Looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol"},{"key":"10.1038\/s41379-020-00679-5_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1038\/s41379-020-00679-5_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"10.1038\/s41379-020-00679-5_bib12","doi-asserted-by":"crossref","first-page":"iv135","DOI":"10.1093\/annonc\/mdz154.026","article-title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","volume":"30","author":"Finn","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib13","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-020-00679-5_bib15","doi-asserted-by":"crossref","first-page":"51936","DOI":"10.18632\/oncotarget.17232","article-title":"PD1 signal transduction pathways in T cells","volume":"8","author":"Arasanz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-020-00679-5_bib16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl J Med"},{"key":"10.1038\/s41379-020-00679-5_bib17","first-page":"858","article-title":"Programmed death 1 immune checkpoint inhibitors","volume":"13","author":"Trivedi","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1038\/s41379-020-00679-5_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-020-00679-5_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/s41379-020-00679-5_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2035","article-title":"Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies","volume":"37","author":"Ali","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1038\/s41379-020-00679-5_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"10.1038\/s41379-020-00679-5_bib25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1038\/s41379-020-00679-5_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-00679-5_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00679-5_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/s41379-020-00679-5_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab induces sustained liver injury in a patient with malignant melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern Med"},{"key":"10.1038\/s41379-020-00679-5_bib30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2217\/imt-2016-0057","article-title":"Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma","volume":"8","author":"Simonelli","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1038\/s41379-020-00679-5_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1038\/s41379-020-00679-5_bib32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest N. Drugs"},{"key":"10.1038\/s41379-020-00679-5_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.14735\/amko2019133","article-title":"Hepatic injury induced by a single dose of nivolumab - a case report and literature review","volume":"32","author":"Kopecky","year":"2019","journal-title":"Klin Onkol"},{"key":"10.1038\/s41379-020-00679-5_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/pin.12812","article-title":"Fulminant hepatitis as an immune-related adverse event after nivolumab treatment","volume":"69","author":"Inamori","year":"2019","journal-title":"Pathol Int"},{"key":"10.1038\/s41379-020-00679-5_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin Ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-00679-5_bib37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-00679-5_bib38","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.1038\/s41379-020-00679-5_bib39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1038\/s41379-020-00679-5_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-00679-5_bib41","doi-asserted-by":"crossref","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315\u201329.","DOI":"10.1002\/hep.31227"},{"key":"10.1038\/s41379-020-00679-5_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/imt-2018-0187","article-title":"PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity","volume":"11","author":"Black","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1038\/s41379-020-00679-5_bib43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1038\/s41379-020-00679-5_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"10.1038\/s41379-020-00679-5_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1038\/s41379-020-00679-5_bib46","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-020-00679-5_bib47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00679-5_bib48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00679-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00679-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00679-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:37:59Z","timestamp":1760229479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222006482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0893395222006482"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-00679-5","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-00679-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}